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ABSTRACT 
According to the American Cancer Society, cancer is a group of diseases 
characterized by uncontrolled growth and spread of abnormal cells. The genetic 
alterations that cause such uncontrolled growth can disrupt the proper functioning of 
affected organ systems and, ultimately, can result in death. It has been suggested in 
recent studies that chromatin remodeling machinery may play an important role in the 
prevention of these diseases (1). The CHD2 gene (Chromo-domain Helicase DNA 
binding protein 2) is a protein thought to play an essential role in the process of 
chromatin remodeling, and this gene is present in a chromosomal region that is frequently 
lost in various cancers. Thus, in an effort to understand the role of CHD2 deficiency in 
cancer formation, we have generated a mutant mouse model that is deficient for Chd2 
expression. Preliminary data indicate that the Chd2 deficient mice are susceptible to 
cancer formation. Our latest research involves the identification of the region of the 
CHD2 protein that allows it to enter the nucleus, where chromatin remodeling takes 
place. Computational analysis of the protein indicates the presence of four putative 
nuclear localization signals (NLS) that may be responsible for this entry into the nucleus. 
Three of these signals are located in the C-terminus end of the protein while the fourth is 
located near the N-terminus of the protein. We generated a CHD2 expression clone that 
contains only the N-terminus signal, and an HA-tag has been attached. The expression of 
this protein fragment was analyzed by immuno-fluorescence and found to localize within 
the nucleus with only the first putative NLS. 
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BACKGROUND 
Chromatin Structure and Remodeling 
Gene regulation is an essential ability in living cells, and one way this is achieved 
in eukaryotic cells is with the chromatin structure of DNA. The DNA found in a 
eukaryotic chromosome is found in association with histones and other small proteins in 
a complex referred to as chromatin. Five types of histones are present in chromatin, and 
they are designated HI, H2A, H2B, H3, and H4 (2). 
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Figure 1. The packaging of DNA in a eukaryotic cell from "beads on a string" to 
chromosome form. 
Chromatin contains repeating structural units often described as "beads on a 
string" known as nucleosomes which contain approximately 1.8 turns of DNA around a 
core particle of histone proteins. The core is composed of an octamer of histones: two 
each ofH2A, H2B, H3, and H4 histones. About 146 base pairs are tightly bound to this 
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core while another 20 base pairs are associated with the HI histone (2). The DNA is then 
condensed further and tightly packed into chromosome form (see Figure 1). 
DNA remains associated with these proteins through electrostatic forces between 
the negatively charged phosphate groups in the DNA backbone and the positively 
charged amino acids, such as lysine and arginine, found in the amino terminal tail of the 
histone proteins. These proteins can be covalently modified through the addition of 
acetyl, methyl, or phosphate groups which, in tum, affect the affinity of the histones for 
the DNA (3-4). These modifications are important to biological processes including 
DNA replication, gene expression, chromatin assembly, condensation, and cell division. 
Histone variants as well as non-histone chromosomal proteins such as high mobility 
group proteins can also be incorporated to affect both chromatin structure and activity 
(5). These characteristics are involved in chromatin remodeling which allow certain 
factors to interact with the DNA and can be used in transcription, replication, repair, 
recombination, and nucleosome assembly (6-17). The exact mechanism of chromatin 
remodeling is not known, and this is an active and ongoing field of research. 
Chromodomain Helicase DNA Binding Proteins 
One group of proteins thought to be important in this process of chromatin 
remodeling is the chromodomain helicase DNA binding (CHD) proteins. This family of 
proteins was characterized in the late 1990's (18-20). The presence of at least eight 
n1errlbers of the CHD family in mammals suggests that these proteins might have diverse 
functional roles in higher eukaryotes (21, 22). Several conserved domains among the 
proteins point to roles in chromatin remodeling and transcriptional control. Common 
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domains among the proteins include the chromodomain (Chromatin organization 
modifer), SNF2-related ATP-dependent helicase domain, DNA binding domains, and the 
C-terminal helicase domain. 
The chromodomain portion can be used to self associate and interacts with the 
heterochromatic regions at centromeres, telomeres and polytene chromosomes (23, 24). 
It is thought that the helicase regions playa role in the unwinding of DNA and in 
destabilizing protein-DNA interactions (21, 13). Both CHD3 and CHD4 have provided 
information on this family of proteins as they were isolated from the nucleosome 
remodeling and histone deacetylation complex (NuRD) in Hela cells which is a complex 
that has been implicated in playing a major role in the organization of higher order 
chromatin complexes and gene repression (25, 27, 28). 
CHD1ICHD2 Sub-family 
CHD 1 and CHD2 belong to a sub-family within the CHD proteins. They share a 
high degree of homology within their chromodomains and their Myb-related DNA­
binding domains, and unlike other CHD proteins, they also contain an HMG-1 domain 
that is present in high mobility group (HMG) proteins (29). The Myb DNA binding 
domain (DBD) is well conserved, and several proteins with Myb-related DBD's have 
been implicated in the regulation of cell proliferation, differentiation, and apoptosis (30). 
HGM-1 domains (A+T hooks) bind to DNA and chromatin and induce short and long 
range changes in the structure of their binding sites (31). These domains are thought to be 
involved in transcription, replication, recombination, and repair, and they are known to 
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playa role in preventing cancer formation due to these activities and their effect on 
cellular proliferation (32-34). 
CHD 1 has recently been shown to associate with active chromatin by binding to 
histone 3 (H3) methylated on lysine 4 (H3K4) which has been known to activate 
transcription (34,35). The H3K4 binding motif (KWxxLxY) found in CHDI is also seen 
in CHD2 which has approximately 60% similarity with CHD 1 at the protein level (34, 
35). This motif is not seen in CHD3 and CHD4 which have been implicated in 
transcriptional repression (36). 
CHD2 Structure and Function 
Few studies have focused on the role of CHD2; thus, its biological role is not yet 
known. The human gene encoding CHD2 is mapped to chromosome 15q26.2 which is a 
region that has been associated with rare genetic disorders that lead to growth retardation, 
cardiac defects and early post natal lethality (37,38). The 99% similarity found between 
the chromodomain and the Myb DNA binding domain of CHD2 with that of CHD 1 
suggests that the protein could be involved in the transcriptional regulation of target 
genes. The presence of the Myb DNA binding domain specifically suggests that CHD2 
is involved in the regulation of genes with Myb-DNA binding sequences. Furthermore, 
deregulation of Myb protein has been seen in human and murine lymphoid cancers 
(39,40). This leads to the hypothesis that CHD2 may be an important protein involved in 
preventing cancer. This is supported by its possible role in DNA repair due to the 
presence of the HGM-l domain, as well as a role in genomic stability and transcriptional 
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regulation as indicated by the helicase domains, chromodomains, and Myb DNA binding 
domain. A representation of the protein motifs found in CHD2 can be seen in Figure 2. 
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Figure 2. Structural motifs seen in the CHD2 protein and the approximate location of gene­
trap insertion. 
CHD2 Nuclear Localization Signals 
In addition to these domains, the CHD2 protein contains four sites that could 
possibly be used as bipartite nuclear localization signals (NLS). These NLS' s are clusters 
of residues that signal the active transport of nuclear proteins into the nucleus by binding 
to molecules such as importins and karyopherins that recognize these distinct targeting 
signals. NLS ' s with a bipartite motif are comprised of two sets of basic residues 
separated by 9-12 residues (41). Three of these sites are found near the C-terminus of the 
protein while the fourth is found close to the N-terminus of the protein. The goal of our 
current experiments has been to determine which sequence is used as the authentic 
nuclear localization signal. The nuclear localization is necessary to the proper 
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functioning of the protein because it must first enter the nucleus in order to interact with 
the chromatin. 
Generation ofCHD2 Deficient Mice 
In order to further study the role of CHD2 in tumor suppression in a mammalian 
model, we generated a mutant mouse model for Chd2 using the Baygenomics genetrap 
ES cell resource (42, 43). One of the ES cell clones that had been characterized to have a 
genetrap insertion within the Chd2 gene was represented in the Baygenomics ES cell 
library. The Chd2 trapped ES cells were obtained from Baygenomics and analyzed by 
PCR to confirm Chd2 disruption by using primers that were specific for Chd2 and the 
gene-trap sequences. Sequencing of the PCR product indicated that the gene trap has 
indeed integrated within intron 27 (1563 base pairs from the beginning of the intron) of 
the Chd2 gene. The insertion of the gene-trap results in the loss of 595 amino acids at the 
C-terminus and results in the formation of a Chd2-p-gal-neomycin fusion gene. Figure 2 
shows the insertion site of the gene-trap vector within the Chd2 gene and the RFLP 
fragments generated due to the insertion. The ES cells confirmed for Chd2 deletion were 
used for blastocyst injections using the micro-injection services at the University of 
Massachusetts Medical School, Worcester and the subsequent generation of chimeric 
founder mice. Out of the seven high degree chimeras obtained from the blastocyst 
injections, analysis of the first three litters from all founder males indicated that two of 
the chimeric founders produced agouti germ line litters for Chd2 deletion. The colonies 
from the two founders were expanded further for the analysis of the mutant offspring. 
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Figure 3. Genotype analysis of Chd2 mutant animals and cell lines. Schematic 
representation of wild type and trapped Chd2 alleles (top panel) is shown above. The expected 
sizes of the genomic DNA fragments obtained from Xbal digestion are indicated along with the 
probe (dark rectangle) used for the southern blot analysis. Southern blot analysis of genomic 
DNA isolated from representative mouse embryonic fibroblasts (MEF) and mouse tails is shown 
in the middle panel along with the genotypes and the sizes of DNA fragments. 
Analysis ofthe mutant Chd2-fusion protein localization 
At the protein level, the insertion of the gene trap was determined to be 
downstream of the HMG-l domain that leads to the loss of 585 amino-acids at the C-
terminus of the Chd2 protein. Analysis of the Chd2 protein indicated that the insertion of 
the gene trap also results in the loss of 3 out of the 4 putative nuclear localization signals. 
This further indicated that the disruption of Chd2 will lead to the absence of the protein in 
the nucleus. To confirm the absence of the Chd2 protein in the nucleus, we used 
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antibodies against the ~-galactosidase and found that the Chd2-~-gal-neomycin fusion 
gene product was localized only in the cytoplasm Figure 3). 
Figure 4. Absence of Chd2-~-gal-neomycin fusion protein in the nuclei of Chd2 mutant 
MEFs. FITC-conjugated antibodies specific for ~-galactosidase were used for detecting the 
fusion protein. Please note the exposure times were the same for both the cell lines that were 
grown on the same chamber slide. 
Although this procedure confirmed that our mutant gene was not entering the 
nucleus, we did not know if this was because the putative NLS at the N-terminal end was 
not functioning as a nuclear localization signal in the absence of the other three NLS' s or 
if the size of the Chd2-~-gal-neomycin fusion gene was serving to block the gene from 
entering the nucleus. Our first step in testing the authenticity of this NLS site was to 
make a clone of the first 447 amino acids which contains only the first NLS sequence in 
addition to a hemagglutinin (HA) tag, transfecting these clones into a mammallian cell 
line, and analyzing the clone with immuno-fluorescence. We will also attach a FLAG-
tag to the clone as well as further clones of varying sizes, and western blot analysis will 
be performed. This combined information will then be used to determine which NLS is 
(are) the authentic sequence(s) used by the protein for entry into the cell. This will 
provide more information on the CHD2 gene, and it will allow further research to be 
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conducted on the putative sequences that are not actually used as nuclear localization 
signals. 
MATERIALS AND METHODS 
Generation ofChd2 gene fragments in mammalian expression vector 
To obtain clones of the Chd2 protein, the cDNA sequence of human CHD2 was 
blasted with mouse Chd2 and found to have approximately 94% homology. A complete 
clone of Chd2 was not available; however, a Chd2 clone, M2021, available from Open 
Biosystems was found to show 99.9% homology to the first 520 base pairs (bp) of the 
human CHD2. Another clone, M5007, contained 3430bp of Chd2 with the first 80bp of 
this section overlapping with the last 80bp of the M2021 clone. The M2021 clone was 
available in the PT7T3D-PacI bacterial vector, and the M5007 had been cloned in the 
pSport6 mammalian vector. In order to begin our experiments, we first set out to place 
both segments in the same mammalian expression vector, pSport6, in order to express the 
peptide in mammalian cells. First, M2021 was cut from PT7T3 D-Pac! with restriction 
enzymes XhoI and NotI. Then, M5007 was cut from pSport6 using SaIl and NotI. 
Digestion with XhoI and SaIl results in compatible ends. M2021 was then ligated into 
the empty pSport6 vector and transformed into JMI09 competent cells, and the resulting 
clone was labeled pSP2021. Ligation was confirmed by performing a restriction digest 
on the miniprep colonies with EcoRV and NotI. 
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Generation ofN-terminal tagged peptide fragment ofChd2 
In order to perform analysis with immuno-fluorescence and western blotting, we 
attached an HA-tag to the MS007 clone using tag specific primers. The primers HAX 
and Pvu2fwere used for this process, and the resulting PCR product, S007-HA tag, was 
approximately 9S0bp. This product was then PCR purified and digested with XbaI 
overnight. The clone pSp2021 was also digested overnight with XbaI and with 1: 1 0 
diluted Pvull for 90 minutes. The digested S007-HA and pSp2021 were then ligated and 
transformed into 1Ml 09 competent cells, resulting in the HA-tagged N-terminal peptide 
clone herein referred to as 1 kHA. Colonies were picked, and the resulting minipreps 
were digested with XbaI to confirm the success of the ligation. Further confirmation and 
determination of the orientation of the Chd2 clone within the vector was gained through 
sequencing. A schematic representation of the N-terminal HA-tagged peptide is shown 
in figure S. 
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Figure 5. Structural motifs seen in the N-terminal HA-tagged peptide fragment in 
comparison to the full length CHD2 protein. 
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Expression ofHA -tagged N-terminal peptide in mammalian cells 
The 1 kHA clone was then transfected in to a mammalian cell line (U20S) via 
lipofectamine mediated DNA transfer, and the cells were grown on glass chamber slides. 
After 24 hours, the cells were fixed with 1: I acetone and methanol (10 min), washed with 
Tris buffered saline and blocked for one hour in 10% antibody dilution buffer (ADB) 
from the stock solution containing 3%BSA, 10% goat serum, 0.05% Triton X-I 00 in PBS 
pH 7.4. The primary anti-HA antibody (1 :1000 dilution in ADB; rabbit) was then added, 
and the slides were incubated in a humidified chamber for four hours at room 
temperature. The slides were then washed three times with ADB buffer and incubated 
for one hour at room temperature with fluorescein isothiocyanate (FITC)-conjugated goat 
anti mouse antibody (1 :500 dilution). The slides were washed with PBS containing 0.2% 
photoflo for ten minutes and PBS containing 0.05% triton X -100 for ten minutes and, 
this was followed by two washes with water and 0.20/0 photoflo for five minutes each. 
Finally, the DNA was counterstained with 4'-6-Diamidino-2-phenylindole (DAPI­
0.1 ug/ml sigma), and the slides were mounted with anti-fade reagent overnight. Images 
of the cells were captured using a Zeiss fluorescent microscope. 
RESULTS 
Analysis of the expression patterns ofHA-tagged N-terminal region ofChd2 
indicated that the N-terminal NLS was sufficient for the expression of the Chd2 protein 
fragment within the nucleus. The resulting pictures from the immuno-fluorescent work 
are shown in figure 6A. The presence of the HA-tagged peptide stains positive for the 
FITC label and appears as a green fluorescent signal while the DAPI staining of the 
Coffey 14 
nuclei of the cells appears blue. Based on the presence of the green fluorescence seen 
only in the nucleus, we can conclude that the 1kHA peptide can actually enter the 
nucleus. Therefore the first NLS for the CRD2 protein is authentic and sufficient for 
nuclear localization. This is an interesting and surprising result considering the fact that 
CHD2 shares a high homology with CRD 1 that has a single NLS signal at the C-
terminus. Despite this result, the mutant Chd2 protein that retains this NLS signal and an 
additional peptide of ~1300 amino acids comprised of the p-galactosidase-neomycin 
fusion gene does not localize to the nucleus (Figure 6B). One probable reason for the 
localization of the mutant protein in the cytoplasm (and not within the nucleus) may be 
the presence of the p-gal-neomycin fusion peptide. We propose that the presence of the 
bacterial- p-galactosidase peptide sequence may prevent its nuclear localization. 
A. 
B. 

Figure 6. (A.) Nuclear localization of lK-HA Chd2 fragment in mammalian U20S cells. 
(B.) Cytoplasmic localization of the Chd2 mutant protein in mouse embryonic fibroblasts. 
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FUTURE EXPERIMENTS 
In the future, we hope to confirm the results of the HA tag immuno-fluorescence 
work by adding a Flag tag to the CHD2 clones. In addition, nuclear and cytoplasmic 
fractions will be analyzed with western-blot assays. We will also express additional 
regions of the Chd2 protein by cloning a larger region of the gene and identify interacting 
proteins using mass spectrometry. 
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